Literature DB >> 17263668

Basic science; metallothionein I and II attenuate the thalamic microglial response following traumatic axotomy in the immature brain.

Emily G Potter1, Ying Cheng, Jay Brandon Knight, Heather Gordish-Dressman, JoAnne E Natale.   

Abstract

The clinical manifestations of inflicted traumatic brain injury in infancy most commonly result from intracranial hemorrhage, axonal stretch and disruption, and cerebral edema. Often hypoxia ischemia is superimposed, leading to early forebrain and later thalamic neurodegeneration. Such acute and delayed cellular injury activates microglia in the CNS. Although activated microglia provide important benefits in response to injury, microglial release of reactive oxygen species can be harmful to axotomized neurons. We have previously shown that the antioxidants metallothionein I and II (MT I & II) promote geniculocortical neuronal survival after visual cortex lesioning. The purpose of this investigation was to determine the influence of MT I & II on the density and rate of thalamic microglial activation and accumulation following in vivo axotomy. We ablated the visual cortex of 10-day-old and adult MT I & II knock out (MT(-/-)) and wild-type mice and then determined the density of microglia in the dorsal lateral geniculate nucleus (dLGN) over time. Compared to the wild-type strain, microglial activation occurred earlier in both young and adult MT(-/-) mice. Similarly, microglial density was significantly greater in young MT(-/-) mice 30, 36, and 48 hours after injury, and 3, 4, and 5 days after injury in MT(-/-) adults. In both younger and older mice, time and MT I & II deficiency each contributed significantly to greater microglial density. Only in younger mice did MT I & II expression significantly slow the rate (density x time) of microglial accumulation. These results suggest that augmentation of MT I & II expression may provide therapeutic benefits to infants with inflicted brain injury.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17263668     DOI: 10.1089/neu.2006.0056.R1

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  8 in total

1.  Up-regulation of metallothionein gene expression in parkinsonian astrocytes.

Authors:  Gregory J Michael; Sharmin Esmailzadeh; Linda B Moran; Lynne Christian; Ronald K B Pearce; Manuel B Graeber
Journal:  Neurogenetics       Date:  2011-07-29       Impact factor: 2.660

2.  FLT-3 expression and function on microglia in multiple sclerosis.

Authors:  Cynthia A DeBoy; Horea Rus; Cosmin Tegla; Cornelia Cudrici; Melina V Jones; Carlos A Pardo; Donald Small; Katharine A Whartenby; Peter A Calabresi
Journal:  Exp Mol Pathol       Date:  2010-05-31       Impact factor: 3.362

3.  Deleterious effects of minocycline after in vivo target deprivation of thalamocortical neurons in the immature, metallothionein-deficient mouse brain.

Authors:  Emily G Potter; Ying Cheng; JoAnne E Natale
Journal:  J Neurosci Res       Date:  2009-05-01       Impact factor: 4.164

4.  Increased circulating leukocyte numbers and altered macrophage phenotype correlate with the altered immune response to brain injury in metallothionein (MT)-I/II null mutant mice.

Authors:  Michael W Pankhurst; William Bennett; Matthew T K Kirkcaldie; Adrian K West; Roger S Chung
Journal:  J Neuroinflammation       Date:  2011-12-07       Impact factor: 8.322

5.  Metallothionein (MT) -I and MT-II expression are induced and cause zinc sequestration in the liver after brain injury.

Authors:  Michael W Pankhurst; David A Gell; Chris W Butler; Matthew T K Kirkcaldie; Adrian K West; Roger S Chung
Journal:  PLoS One       Date:  2012-02-17       Impact factor: 3.240

6.  Influence of Transgenic Metallothionein-1 on Gliosis, CA1 Neuronal Loss, and Brain Metal Levels of the Tg2576 Mouse Model of Alzheimer's Disease.

Authors:  Gemma Comes; Yasmina Manso; Anna Escrig; Olaya Fernandez-Gayol; Paula Sanchis; Amalia Molinero; Mercedes Giralt; Javier Carrasco; Juan Hidalgo
Journal:  Int J Mol Sci       Date:  2017-01-26       Impact factor: 5.923

7.  CuII(atsm) Attenuates Neuroinflammation.

Authors:  Xin Yi Choo; Jeffrey R Liddell; Mikko T Huuskonen; Alexandra Grubman; Diane Moujalled; Jessica Roberts; Kai Kysenius; Lauren Patten; Hazel Quek; Lotta E Oikari; Clare Duncan; Simon A James; Lachlan E McInnes; David J Hayne; Paul S Donnelly; Eveliina Pollari; Suvi Vähätalo; Katarína Lejavová; Mikko I Kettunen; Tarja Malm; Jari Koistinaho; Anthony R White; Katja M Kanninen
Journal:  Front Neurosci       Date:  2018-09-24       Impact factor: 4.677

8.  Emergence of delayed methylmercury toxicity after perinatal exposure in metallothionein-null and wild-type C57BL mice.

Authors:  Minoru Yoshida; Natsuki Shimizu; Megumi Suzuki; Chiho Watanabe; Masahiko Satoh; Kouki Mori; Akira Yasutake
Journal:  Environ Health Perspect       Date:  2008-06       Impact factor: 9.031

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.